The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including at least one growth factor, a first layer including at least one of one or more interleukins and capsaicin, and a second layer including an antigen operatively arranged to activate an innate immune system.

Embodiments herein described provide devices for identifying and collecting rare cells or cells which occur at low frequency in the body of a subject, such as, antigen-specific cells or disease-specific cells. More specifically, the devices are useful for trapping immune cells and the devices contain a physiologically-compatible porous polymer scaffold, a plurality of antigens, and an immune cell-recruiting agent, wherein the plurality of antigens and the immune cell recruiting agent attract and trap the immune cell in the device. Also provided are pharmaceutical compositions, kits, and packages containing such devices. Additional embodiments relate to methods for making the devices, compositions, and kits/packages. Further embodiments relate to methods for using the devices, compositions, and/or kits in the diagnosis or therapy of diseases such as autoimmune diseases or cancers.

Embodiments herein described provide devices for identifying and collecting rare cells or cells which occur at low frequency in the body of a subject, such as, antigen-specific cells or disease-specific cells. More specifically, the devices are useful for trapping immune cells and the devices contain a physiologically-compatible porous polymer scaffold, a plurality of antigens, and an immune cell-recruiting agent, wherein the plurality of antigens and the immune cell recruiting agent attract and trap the immune cell in the device. Also provided are pharmaceutical compositions, kits, and packages containing such devices. Additional embodiments relate to methods for making the devices, compositions, and kits/packages. Further embodiments relate to methods for using the devices, compositions, and/or kits in the diagnosis or therapy of diseases such as autoimmune diseases or cancers.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

A syringe containing a compressible porous matrix, which compressible porous matrix has in it a pharmaceutical in a soluble glass, Methods of producing and using the syringe, and compressible porous matrix inserts for insertion into a syringe barrel are also provided.

An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including at least one growth factor, a first layer including at least one of one or more interleukins and capsaicin, and a second layer including an antigen operatively arranged to activate an innate immune system.

Methods of preparing a human birth tissue material are provided. A placental construct for treatment of a disease or condition is also provided. A kit including at least one placental construct and at least one structural carrier is provided. A catheter for recovering amniotic fluid is also provided.

Myosin heavy chain 11 (MYH11)-siRNA-eluting, calponin 1 (CNN1)-siRNA-eluting, leiomodin 1 (LMOD)-siRNA-eluting, smoothelin (SMTN)-siRNA-eluting, tropomyosin (TPM)-siRNA-eluting, caldesmon 1 (CALD)-siRNA-eluting, actinin (ACTN)-siRNA-eluting, actin alpha (ACTA)-siRNA-eluting, and actin beta (ACTB)-siRNA-eluting medical device capable of selective and significant inhibition of vascular smooth muscle cells (VSMC) in the same or even higher order of magnitude of sirolimus or analogs and paclitaxel or analogs that are cell antiproliferative drugs currently used in drug-eluting stents (DES), whereas said MYH11-siFRNA-eluting, CNN1-siFRNA-eluting, LMOD-siRNA-eluting, SMTN-siRNA-eluting, TPM-siRNA-eluting, CALD-siRNA-eluting, ACTN-siRNA-eluting, ACTA-siRNA-eluting, and ACTB-siRNA-eluting medical devices promote early medical device struts coverage and/or vascular re-endothelialization compared to the current DES that elute cell antiproliferative drugs such as sirolimus or analogs and, paclitaxel or analogs.

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.